South Africa Takes Progressive Strides in Tuberculosis Research Funding

As the world grapples with various health crises, the fight against tuberculosis (TB) remains a pivotal battleground, particularly in countries with a high burden of the disease. A recent Treatment Action Group (TAG) report casts a spotlight on South Africa's TB research funding landscape, revealing that the nation is at the forefront in meeting critical research investment goals amidst a global shortfall.

South Africa has consistently dedicated resources toward TB research, achieving its "fair share target" in specific years, as defined by the TAG and endorsed by global partnerships like the Stop TB Partnership. The "fair share target" is tailored to each country, demanding they contribute 0.1% of their gross domestic expenditure on R&D (Gerd) to TB research.

This approach aims to galvanize a collective effort from nations to reach the global TB research funding goals. South Africa's commitment has seen it fulfilling its fair share target in multiple years (2018 and 2021) and stands as one of only six nations to have done so since 2018. Despite a noticeable dip between 2019 and 2020, the country's TB research funding rebounded in 2021, thanks in part to the National Research Foundation (NRF) and National Health Laboratory Services (NHLS) reporting their contributions for the first time.

International pledges, such as those made at the UN High-Level Meetings on Tuberculosis, underline the necessity for a ramp-up in funding—yet realise that global contributions are falling short. South Africa's efforts reflect a determination to reverse this trend and uphold promises made at these assemblies, with Health Minister Joe Phaahla echoing the call for nations to honour their commitments.

The majority of TB research funding in South Africa for 2022 can be credited to public entities like the Department of Science and Innovation (DSI) and the South African Medical Research Council (SA MRC), which collectively channelled nearly R69 million into the mission. This is complemented by substantial international participation, as South African research units also receive significant funding from global partners.

South Africa predominantly invested in basic science research in 2022, but also extended resources to push for advancements in TB medication, diagnostic tools, vaccines, and infrastructural support for research—a holistic approach crucial in the fight against TB.

Moving forward, with a heightened $5-billion annual TB research funding target set for 2027 by the UN, South Africa's fair share has been recalculated to $7.7-million, adjusting for global Gerd growth. It's a clarion call for South Africa—and indeed all nations—to bolster their efforts and financially back the battle to eliminate TB.

The TAG report's insights not only serve as a wake-up call for the world but also as testament to South Africa's pledge to take meaningful steps in TB research funding, showcasing its role in global health security while learning and building from the nation's investment blueprint.